Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib Combinations in ALK/ROS1+ Lung Cancer
NCT04292119Phase 2Unknown
- Sponsor
- Massachusetts General Hospital
- Start
- May 2020
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lorlatinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Maximum Tolerated Dose at 21 days and Objective Response Rate at 24 months. Status: unknown.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04292119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04292119.